Steven Cohen Grifols Sa Transaction History

Point72 Asset Management, L.P.

$39.3 Billion
Q1 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Grifols Sa stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 143,145 shares of GRFS stock, worth $901,813. This represents 0.0% of its overall portfolio holdings.

Number of Shares

143,145

Previous 915,400 84.36%

Holding current value

$901,813

Previous $10.6 Million 90.97%

% of portfolio

0.0%

Previous 0.03%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$5.47 - $11.38 $4.22 Million - $8.79 Million	-772,255 Reduced 84.36%	143,145 $956,000
Q4 2023 Feb 14, 2024	SELL	$7.71 - $11.56 $20.1 Million - $30.2 Million	-2,610,575 Reduced 74.04%	915,400 $10.6 Million
Q3 2023 Nov 14, 2023	BUY	$8.91 - $10.91 $14.4 Million - $17.6 Million	1,617,275 Added 84.73%	3,525,975 $32.2 Million
Q2 2023 Aug 14, 2023	BUY	$7.14 - $9.29 $13.6 Million - $17.7 Million	1,908,700 New	1,908,700 $17.5 Million
Q3 2022 Nov 14, 2022	BUY	$5.95 - $14.3 $12.8 Million - $30.7 Million	2,149,771 Added 919.38%	2,383,600 $14.7 Million

Q2 2022 Aug 15, 2022	BUY	$10.6 - $13.28 $2.48 Million - $3.11 Million	233,829 New	233,829 $2.78 Million
Q2 2020 Aug 14, 2020	SELL	$18.24 - $21.45 $7.65 Million - $9 Million	-419,620 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$16.28 - $25.63 $12,698 - $19,991	-780 Reduced 0.19%	419,620 $8.45 Million
Q4 2019 Feb 14, 2020	SELL	$19.57 - $23.52 $6.09 Million - $7.32 Million	-311,342 Reduced 42.55%	420,400 $9.79 Million
Q3 2019 Nov 15, 2019	BUY	$19.85 - $22.76 $14.5 Million - $16.7 Million	731,742 New	731,742 $14.7 Million

Others Institutions Holding GRFS

# of Institutions

150

Shares Held

140M

Call Options Held

3.54M

Put Options Held

919K

View Full List

About Grifols SA

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $4.28B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

More about GRFS

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account